Aires Pharmaceuticals appoints Edwin L. Parsley as CMO
Aires Pharmaceuticals has hired Ed Parsley, D.O., as chief medical officer. Parsley will be responsible for all clinical development activities for Aironite, the company's lead product for treatment of pulmonary arterial hypertension (PAH).
Parsley joins Aires from Pfizer where he was the clinical lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's approved drug to treat PAH. He previously worked at CSL Biotherapies and Encysive Pharmaceuticals.